Diamond Hill Capital Management LLC Investment Advisor Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, Holdings Channel.com reports. The fund purchased 252,559 shares of the medical research company’s stock, valued at approximately $126,623,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TMO. Legacy Wealth Managment LLC ID lifted its position in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 22 shares during the period. Allied Private Wealth LLC acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth approximately $26,000. High Note Wealth LLC increased its stake in Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 29 shares in the last quarter. Swiss RE Ltd. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $28,000. Finally, JPL Wealth Management LLC purchased a new stake in Thermo Fisher Scientific during the third quarter worth $28,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the completion of the sale, the chief operating officer owned 24,651 shares of the company’s stock, valued at $13,927,815. The trade was a 1.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 5,850 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $580.00, for a total value of $3,393,000.00. Following the completion of the transaction, the vice president owned 14,784 shares of the company’s stock, valued at $8,574,720. The trade was a 28.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 52,053 shares of company stock worth $30,643,589 in the last three months. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Down 0.3%

Thermo Fisher Scientific stock opened at $586.62 on Tuesday. The stock has a 50-day moving average price of $531.72 and a 200 day moving average price of $508.48. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99. The stock has a market cap of $216.90 billion, a PE ratio of 31.56, a P/E/G ratio of 2.39 and a beta of 0.84. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the prior year, the firm earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Stifel Nicolaus set a $650.00 price target on Thermo Fisher Scientific in a research report on Wednesday, August 5th. Royal Bank Of Canada increased their price objective on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research note on Friday, July 24th. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Finally, Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.